An important role of the hepcidin-ferroportin signaling in affecting tumor growth and metastasis

Acta Biochimica et Biophysica Sinica

Volumn 47, Issue 9, 2015, Pages 703-715

  Guo, Wenli ^a   Zhang, Shuping ^a,b   Chen, Yue ^a,c   Zhang, Daoqiang ^d   Yuan, Lin ^d   Cong, Haibo ^d   Liu, Sijin ^a  

^a RESEARCH CENTER FOR ECO ENVIRONMENTAL SCIENCES   (China)

^b Massachusetts Institute of Technology   (United States)

^c SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^d WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

cancer; epithelial to mesenchymal transition (EMT); ferroportin; hepcidin; iron; metastasis

Indexed keywords

CATION TRANSPORT PROTEIN; HAMP1 PROTEIN, MOUSE; HEPCIDIN; METAL TRANSPORTING PROTEIN 1;

ANIMAL; BREAST TUMOR; CELL PROLIFERATION; FEMALE; GENETICS; HUMAN; METABOLISM; METASTASIS; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HEPCIDINS; HUMANS; MICE; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION;

EID: 84940846945     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmv063     Document Type: Article

References (57)

1. Ganz T. Systemic iron homeostasis. Physiol Rev 2013, 93: 1721-1741.
2. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011, 117: 4425-4433.
3. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, et al. Hepcidin regulates cellular iron ef flux by binding to ferroportin and inducing its internalization. Science 2004, 306: 2090-2093.
4. Zhang S, Chen Y, Guo W, Yuan L, Zhang D, Xu Y, Nemeth E, et al. Disordered hepcid in-ferroportin signaling promotes breast cancer growth. Cell Signal 2014, 26: 2539-2550.
5. Pinnix ZK, Miller LD,WangW, D'Agostino R Jr., Kute T,Willingham MC, Hatcher H, et al. Ferroport in and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2010, 2: 43ra56.
6. Durigova A, Lamy PJ, Thezenas S, Pouderoux S, Montels F, Romieu G, Gutowski M, et al. Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and soluble transferrin receptor quantification. Clin Chem Lab Med 2013, 51: 1833-1841.
7. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood 2008, 112: 4292-4297.
8. Maes K, Nemeth E, Roodman GD, Huston A, Esteve F, Freytes C, Callander N, et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood 2010, 116: 3635-3644.
9. Tanno T, Rabel A, Alley ne M, Lee YT, Dahut WL, Gulley JL, Miller JL. Hepcidin, anaemia, and prostate cancer. BJU Int 2011, 107: 678-679.
10. Chen Y, Zhang Z, Yang K, Du J, Xu Y, Liu S. Mye loid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportinconducted iron egress. Oncogene 2014. doi: 10.1038/onc.2014.310.
11. XiongW,Wang L, Yu F. Regulation of cellular iron metabolism and its implications in lung cancer progression. Med Oncol 2014, 31: 28.
12. Borsig L. Heparin as an inhibitor of cancer progression. Prog Mol Biol Transl Sci 2010, 93: 335-349.
13. De Domenico I, Ward DM, Nemeth E, Vaughn MB, Musci G, Ganz T, Kaplan J. The molecular basis of ferroportin-linked hemochromatosis. Proc Natl Acad Sci USA 2005, 102: 8955-8960.
14. Costa Y, Ding JJ, Theunissen TW, Faiola F, Hore TA, Shliaha PV, Fidalgo M, et al. NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. Nature 2013, 495: 370-374.
15. Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 2009, 69: 8742-8751.
16. WangW, Deng Z, Hatcher H, Miller LD, Di X, Tesfay L, Sui G, et al. IRP2 regulates breast tumor growth. Cancer Res 2014, 74: 497-507.
17. Viatte L, Lesbordes-Brion J C, Lou DQ, Bennoun M, Nicolas G, Kahn A, Canonne-Hergaux F, et al. Deregulation of proteins involved in iron metabolism in hepcidin-deficient mice. Blood 2005, 105: 4861-4864.
18. Ram os E, Ruchala P, Goodnough JB, Kautz L, Preza GC, Nemeth E, Ganz T. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood 2012, 120: 3829-3836.
19. Chen Y,Zhang S,Wang X,Guo W,Wang L,Zhang D,Yuan L,et al. Disordered signaling governing ferroportin transcription favors breast cancer growth Cell Signal, 2015, 27, 168-176
20. Zhang C, Zhang S, Zhang Z, He J, Xu Y, Liu S. ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc. Oncogene 2014, 33: 5582-5591.
21. Zhang S, Wang Z, Wang L, Liu S. AG490: an inhibitor of hepcidin expression in vivo. World J Gastroenterol 2011, 17: 5032-5034.
22. Gonzalez-Iglesias H, Fernandez-Sanchez ML, Lopez-Sastre J, Sanz-Medel A. Nutritional iron supplementation studies based on enriched (57) Fe, added to milk in rats, and isotope pattern deconvolution-ICP-MS analysis. Electrophoresis 2012, 33: 2407-2415.
23. Chen Y,Wang Z, Xu M,Wang X, Liu R, Liu Q, Zhang Z, et al. Nanosilver incurs an adaptive shunt of energy metabolism mode to glycolysis in tumor and no ntumor cells. ACS Nano 2014, 8: 5813-5825.
24. Lesbordes-Brion JC, Viatte L, Bennoun M, Lou DQ, Ramey G, Houbron C, Hamard G, et al. Targeted disruption of the hepcidin 1 gene re sults in severe hemochromatosis. Blood 2006, 108: 1402-1405.
25. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001, 276: 7811-7819.
26. Lou DQ, Nicolas G, Lesbordes JC, Viatte L, Grimber G, Szajnert MF, Kahn A, et al. Functional differences between hepcidin 1 and 2 in transgenic mice. Blood 2004, 103: 2816-2821.
27. Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer 2013, 13: 342-355.
28. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000, 275: 19906-19912.
29. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000, 40 3: 776-781.
30. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006, 26: 323-342.
31. Liu S, Li S, Du Y. Polychlorinated biphenyls ( PCBs) enhance metastatic properties of breast cancer cells by activating Rho-associated kinase (ROCK). PLoS ONE 2010, 5: e11272.
32. Dolbeare F. Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part III. Proliferation in normal, injured and diseased tissue, growth factors, differentiation, DNA replication sites and in situ hybridization. Histochem J 1996, 28: 531-575.
33. Crane AM, Bhattacharya SK. The use of bromodeoxyuridine incorporation assays to assess corneal stem cell proliferation. Methods Mol Biol 2013, 1014: 65-70.
34. Qu G, Liu S, Zhang S, Wang L, Wang X, Sun B, Yin N, et al. Graphene oxide induces toll-like receptor 4 (TLR4)-dependent necrosis in macrophages. ACS Nano 2013, 7: 5732-5745.
35. Kaufhold S, Bonavida B. Central role of Snail1 in the regulation of EMTand resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res 2014, 33: 62.
36. Teng Y , Li X. The roles of HLH transcription factors in epithelial mesenchymal transition and multiple molecular mechanisms. Clin Exp Metastasis 2014, 31: 367-377.
37. Gheldof A, Hulpiau P, van Roy F, De Craene B, Berx G. Evolutionary functional analysis and molecular regulation of the ZEB transcription factors. Cell Mol Life Sci 2012, 69: 2527-2541.
38. Cha YH, Yook JI, Kim HS, Kim NH. Catabolic metabolism during cancer EMT. Arch Pharm Res 2015, 38: 313-320.
39. Cuyas E, Corominas-Faja B, Menendez JA. The nutritional phenome of EMT-induced cancer stem-like cells. Oncotarget 2014, 5: 3970-3982.
40. Hamabe A, Konno M, Tanuma N, Shima H, Tsunekuni K, Kawamoto K, Nishida N, et al. Role of pyruvate kinase M2 in transcriptional regulation leading to ep ithelial-mesenchymal transition. Proc Natl Acad Sci USA 2014, 111: 15526-15531.
41. Siegel R,Naishadham D,Jemal A. Cancer statistics, 2013 CACancer J Clin 2013, 63, 11-30.
42. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin 2011, 61: 409-418.
43. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organspecific colonization. Nat Rev Cancer 2009, 9: 274-284.
44. Valastyan S,Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147: 275-292.
45. Zhang C, Zhang F. Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities. Protein Cell 2015, 6: 88-100.
46. Torti SV, Torti FM . Cellular iron metabolism in prognosis and therapy of breast cancer. Crit Rev Oncog 2013, 18: 435-448.
47. Wang Q, Zhou J,Zhong D,Wang Q, Huang J. Ferroportin in the progression and prognosis of hepatocellular carcinoma. Eur J Med Res 2013, 18: 59.
48. Miller LD, C offman LG, Chou JW, Black MA, Bergh J, D'Agostino R Jr., Torti SV, et al. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res 2011, 71: 6728-6737.
49. Foub ert E, De Craene B, Berx G. Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression. Breast Cancer Res 2010, 12: 206.
50. Sa telli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 2011, 68: 3033-3046.
51. Savagner P. The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol 2010, 21(Suppl 7): vii89-vii92.
52. Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 2011, 27: 347-376.
53. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013, 13: 97-110.
54. Kothari AN, Mi Z, Zapf M, Kuo PC. Novel clinical therapeutics targeting the epithelial to mesenchymal transition. Clin Transl Med 2014, 3: 35.
55. Steinestel K, Eder S, Schrader AJ, Steinestel J. Clinical significance of epithelial-mesenchymal transition. Clin Transl Med 2014, 3: 17.
56. Zhang Y, Yang JM. Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention. Cancer Biol Ther 2013, 14: 81-89.
57. Kee HJ, Cheong JH. Tumor bioenergetics: an emerging avenue for cancer metabolism targeted therapy. BMB Rep 2014, 47: 158-166.